ClinicalTrials.gg
RecruitingNCT07669415Updated Jul 30, 2026

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

A Phase 2 interventional study of LM-168 and Tislelizumab in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

For Safety introduction phase,this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D).

For Dose expansion phase,this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the document prior to any procedure.
  • Aged ≥18 years old, male or female when sign the Informed consent form (ICF).
  • (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose.
  • ≥ 3 months.
  • In dose escalation stage, participants must have histological or cytological confirmation of recurrent or advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
  • In dose expansion stage, participants must have histological or cytological confirmation of selected advanced solid tumors.
  • Pre-treatment archived tumour tissue (within 5 years) or on treatment could be provided for biomarker analysis optionally.
  • At least one for expansion cohorts per (RECIST) v1.1.
  • Participants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
  • Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study

Exclusion criteria

Exclusion Criteria:

  • Received any other product or treatment within 28 days prior to the first dose of LM-168.
  • Received anti-cytotoxic T-lymphocyte-associated antigen 4 () agents, any other immunotherapy or oncology immune-oncology (IO) drugs within 28 days prior to the first dose of LM-168; or permanently discontinued prior immunotherapy due to immune-related adverse events (irAEs). All adverse events (AEs) from previous anti-tumor treatments have not fully resolved or resolved to Grade 1 prior to screening. Requirement for additional (other than low-dose ) to control irAEs.
  • Received other anti-tumor treatments prior to the first dose of LM-168, as specified below:

    1. Received limited-field palliative radiotherapy within 14 days prior to the first dose (excluding radiotherapy solely for pain control of bone ).
    2. Received chemotherapy, small-molecule targeted agents (e.g., tyrosine kinase inhibitors) or hormonal therapies within 14 days prior to the first dose or within 5 half-lives of the respective agent (whichever is longer).
    3. Received biologic therapy or immunotherapy within 28 days prior to the first dose or within 5 half-lives of the respective agent (whichever is shorter).
    4. Received traditional Chinese medicines with anti-tumor indications within 14 days prior to the first dose.
    5. Received nitrosoureas or mitomycin C within 42 days prior to the first dose.
  • AEs from prior anti-tumor treatments have not recovered to Grade ≤ 1 per Version 6.0. Exceptions include: toxicities assessed by the Investigator to pose no safety risks (e.g., alopecia), long-term radiation-related toxicities with Grade ≤ 2, and hypothyroidism stabilized with hormonal replacement therapy.
  • Uncontrolled tumor-related pain. Participants requiring analgesic treatment must have been on a stable analgesic dose prior to study entry.
  • Known active or .
  • Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
  • Esophageal or gastric varices requiring immediate clinical intervention, or a history of variceal bleeding; except for participants with stable conditions confirmed by endoscopic evaluation within 3 months prior to the first study drug administration.
  • History of hepatic encephalopathy, hepatorenal syndrome, or cirrhosis classified as Class B or higher.
  • Tumor invasion into adjacent vital organs (e.g., aorta, heart, pericardium, superior vena cava, trachea, esophagus, etc.), or at risk of developing esophagotracheal fistula or esophagopleural fistula.
  • Active or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea).
  • History of Grade ≥ 3 reactions to monoclonal antibody-based therapies.
  • Experienced Grade ≥ 3 irAEs during prior immunotherapy, or discontinued prior immunotherapy due to severe or life-threatening irAEs.
  • Received systemic corticosteroids (prednisone equivalent > 10 mg daily) or other systemic immunosuppressive agents (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor agents) within 2 weeks prior to the first dose of LM-168. Topical, ophthalmic, intra-articular, intranasal and inhaled corticosteroids are permitted.
  • Known history of diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis and glomerulonephritis (see Appendix 3 for the complete list of autoimmune diseases). Exception: participants with autoimmune hypothyroidism maintained on a stable dose of thyroid replacement hormones.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonia, interstitial lung disease or severe radiation pneumonitis; or evidence of active pneumonia on chest CT scan during the screening period.
  • Received any within 28 days prior to the first dose.
  • Underwent major surgery or interventional procedures within 28 days prior to the first dose of LM-168 (excluding tumor , puncture and other minor procedures).
  • Severe cardiovascular and cerebrovascular diseases,
  • Uncontrolled or severe concomitant diseases, including ongoing or active infections (e.g., active COVID-19/SARS-CoV-2 infection, syphilis) requiring therapeutic antibiotics and/or other medications. SARS-CoV-2 testing is not mandatory for study enrollment but shall comply with local clinical practice guidelines and standards.
  • History of immunodeficiency disorders, including other acquired or congenital immunodeficiencies; or history of solid organ transplantation, bone marrow transplantation or autologous hematopoietic stem cell transplantation.
  • (HIV) infection, or active hepatitis infection (including tuberculosis, Virus [HBV] and Virus [HCV] infection),
  • History of other within 5 years prior to the first study drug administration. Exceptions include cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-muscle invasive bladder cancer, localized low-risk prostate cancer (defined as Stage ≤ T2a, Gleason score ≤ 6, curatively treated at diagnosis with no biochemical recurrence of prostate-specific antigen [PSA; PSA ≤ 10 ng/mL if tested]), carcinoma in situ of cervix or breast, and other malignancies deemed appropriate for study participation by the Investigator.
  • Females of with a positive pregnancy test or who are breastfeeding.
  • Psychiatric illnesses or disorders that may interfere with study compliance.
  • Any other conditions that render the participants unsuitable for study participation, as determined by the Investigator.

Exclusion Criteria for the Combination cohort with Docetaxel

  1. Prior exposure to taxane-based therapies.
  2. Received strong inhibitors or strong CYP3A4 inducers within 14 days prior to the first dose (see Appendix 5).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    LM-168 + Tislelizumab Safety introduction

    Drug: LM-168 · Drug: Tislelizumab

  • Experimental
    LM-168 Dose Expansion

    Drug: LM-168

  • Experimental
    LM-168 + Tislelizumab Dose Expansion

    Drug: LM-168 · Drug: Tislelizumab

  • Experimental
    LM-168 + Tislelizumab +Other anti-tumor treatments Dose Expansion

    Drug: LM-168 · Drug: Tislelizumab · Drug: Docetaxel injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT)

    Safety introduction phase

    Time frame: 78 Weeks

  2. Objective response rate (ORR)

    Dose expansion phase

    Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

Secondary outcomes

  1. Duration of response (DoR)

    Dose expansion phase

    Time frame: Time from initial response (CR or PR) to date of documented disease progression or death (due to any cause) whichever occurs first, up to approximately 42 months

  2. Disease control rate (DCR)

    Dose expansion phase

    Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

  3. Progression Free Survival (PFS)

    Dose expansion phase

    Time frame: up to 42 months

  4. Overall Survival (OS)

    Dose expansion phase

    Time frame: up to 42 months

  5. AE and SAE

    Safety introduction phase/Dose expansion phase

    Time frame: From signing the ICF until 28 days after EOT or accept other anti-cancer therapy,up to 40 days after last study dose

  6. Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve from time zero to the last quantifiable concentration (AUC last)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  7. Pharmacokinetic (PK) Parameter:Area Under the Concentration-time Curve over a dosing interval (τ) at steady state(AUC tau)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  8. Pharmacokinetic (PK) Parameter:Maximum Observed Concentration(Cmax)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  9. Pharmacokinetic (PK) Parameter:Time to Reach Maximum Concentration(Tmax)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  10. Pharmacokinetic (PK) Parameter:Elimination Half-life(T 1/2)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  11. Pharmacokinetic (PK) Parameter:Maximum Steady-State Concentration(Cmax, ss)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  12. Pharmacokinetic (PK) Parameter:Minimum Steady-State Concentration(Cmin, ss)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  13. Pharmacokinetic (PK) Parameter:Clearance at Steady State(CLss)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  14. Pharmacokinetic (PK) Parameter:Volume of Distribution at Steady State(Vss)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  15. Pharmacokinetic (PK) Parameter:Accumulation Ratio based on AUC(Rac, AUC)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  16. Pharmacokinetic (PK) Parameter:Accumulation Ratio based on Cmax(Rac, Cmax)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  17. Pharmacokinetic (PK) Parameter:Fluctuation Index / Degree of Fluctuation

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  18. immunogenicity Parameter:Anti-Drug Antibody(ADA)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

  19. immunogenicity Parameter:Neutralizing Antibody(Nab)

    safety introduction phase/Dose expansion phase

    Time frame: up to 42 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 25, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07669415
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jul 29, 2026
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

wei wang
Contact
weiwang@Lanovamed.com
021-68889618
liang kong
Contact
Paulkong@lanovamed.com
021-68889618
lin shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion